S1-RBD-Kappa protein (B.1.617.1)_HEK

SARS-CoV-2 (B.1.617.1) RBD mutant from the Kerala variant. Contains amino acid changes E484Q, L452R relative to Wuhan Hu-1. The protein was produced in HEK293 cells and purified from the culture supernatant. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

InVivo has developed a large set of reagents for COVID-19 research and industrial-scale manufacturing of highly sensitive in vitro diagnostic kits. Our portfolio comprises different recombinant versions of the SARS-CoV-2 Spike protein, which were transiently expressed in our high-throughput mammalian HEK cells. These include the full-length Spike protein, the two functional subunits S1 and S2, plus the S1 receptor-binding domain (RBD).

The antigens show high activity and adequate glycosylation and are suitable for the development of highly sensitive immunoassays. To meet the long-term demand for bulk quantities on the gram scale, InVivo offers the production of recombinant Spike antigens from pools of stable CHO cells. The portfolio was recently expanded with several mutant Spike antigens from the recently discovered variants in the UK, South Africa, and Brazil.

These antigens were produced by transient expression in our proprietary HEK system. In addition, we also offer the SARS-CoV-2 nucleocapsid protein from bacterial expression systems for research use. For the industrial-scale manufacture of SARS-CoV-2 detection kits (ELISA, Lateral Flow, and more), InVivo provides different mouse hybridoma monoclonal antibodies, which target SARS-CoV-2 Spike or Nucleocapsid proteins, respectively.

All Spike protein antibodies were validated by ELISA and demonstrate specificity for the S1 subunit of the RBD region. Humanized chimeric recombinant antibodies that target the Spike protein are still in development and will be available soon.